• June 3, 2024 | 8:00 AM - 9:30 AM CT
  PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients
  Abstract: 6015 | Rapid Oral Abstract Session - Head and Neck Cancer

Abstracts Selected for Poster Presentation

• June 2, 2024 | 9:00 AM - 12:00 PM CT
  Phase II trial of immunotherapeutic HPV vaccine PRGN-2009 with pembrolizumab before standard treatment in subjects with newly diagnosed HPV-associated oropharyngeal cancer
  Abstract: 6124 | Poster Session - Head and Neck Cancer
• June 3, 2024 | 9:00 AM - 12:00 PM CT
  A Phase 2 study to evaluate efficacy and safety of PRGN-2009, a novel gorilla adenovirus-based immunotherapy, in combination with pembrolizumab versus pembrolizumab monotherapy in patients with recurrent or metastatic cervical cancer
  Abstract 5623 | Poster Session - Gynecologic Cancer